Apollon Wealth Management’s Actuate Therapeutics ACTU Stock Holding History

Apollon Wealth Management’s Portfolio ACTU Stock Details ACTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-14,013	Closed	-$21.4K	–	1735
2026 Q2	$21.4K	Buy	+14,013	New	+$32.5K	﹤0.01%	1568

Other funds holding ACTU

Gleason Group Prospect, Kentucky $1.13B AUM 12.68% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return

GRWP

Green Ridge Wealth Planning Montville, New Jersey $249M AUM 26.89% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Apollon Wealth Management's ACTU Position: Q3 2026 in Review

Apollon Wealth Management sold out of Actuate Therapeutics (ACTU) in Q3 2026, closing a stake of 14,013 shares — an estimated $21.4K sold.

Apollon Wealth Management first reported a position in ACTU in Q2 2026 and held it in 1 quarter. The position peaked at $21.4K in Q2 2026. 5 funds tracked by Wall St. Rank hold ACTU as of Q3 2026.

Apollon Wealth Management reported no remaining Actuate Therapeutics position as of Q3 2026 after selling out during the quarter.
Apollon Wealth Management sold 14,013 Actuate Therapeutics shares in Q3 2026, an estimated $21.4K.
Apollon Wealth Management first reported a position in Actuate Therapeutics in Q2 2026 and held it in 1 quarter.
Apollon Wealth Management's Actuate Therapeutics position peaked at $21.4K in Q2 2026.
5 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q3 2026.

Based on Apollon Wealth Management's 13F filing for Q3 2026, filed 23 Oct 2026.